HIV i-Base

Treatment activist organisation founded in 2000, working in the UK and internationally to improve quality of care for people living with HIV. Also on Bluesky.

[HIV i-Base @HIViBase]

Unexpected #ViralRebound in people living with #HIV taking GLP-1 #WeightLoss drugs:

https://t.co/97VhQVTi4G

A @Leic_hospital HIV clinic discovered high use of these meds via a patient survey.

#GLP1 #Wegovy #Mounjaro #Ozempic #semaglutide #tirzepatide #HIVpositive #HIVtreatment

[HIV i-Base @HIViBase]

Special report – 3rd London #Chemsex Conference.

An expanding network of excellent but underfunded services and an urgent need for data:

https://t.co/YeUBZD4ql3

Other themes included the importance of living experience and barriers to accessing care.

#HIV @GMHC_UK @lgbtfriend

[HIV i-Base @HIViBase]

Special report – 3rd London #Chemsex Conference.

An expanding network of excellent but underfunded services and an urgent need for data:

https://t.co/YeUBZD4ql3

Other themes included the importance of living experience and barriers to accessing care.

#HIV @GMHC_UK @lgbtfriend

[Academic Medical Education @Academic_MedEdu]

Explore the program of the 9th Nurses & Pharmacists HIV Clinical Forum! Join us on 24 November in Porto or online for expert lectures and discussions on HIV care.

🎓 Free for regular delegates.
📍HF Ipanema Porto

🔗 https://t.co/LwpEPy4H0B

[HIV i-Base @HIViBase]

Major update to US HHS #HIVguidelines for treatment:

https://t.co/HEA12wLjiR

An internationally important update for #HIVtreatment prescribers and community activists alike. Each section also now highlights the knowledge gaps where future research should focus.

#HIV #HIVcare

[HIV i-Base @HIViBase]

Major update to US HHS #HIVguidelines for treatment:

https://t.co/HEA12wLjiR

An internationally important update for #HIVtreatment prescribers and community activists alike. Each section also now highlights the knowledge gaps where future research should focus.

#HIV #HIVcare

[HIV i-Base @HIViBase]

#PrEP efficacy depends on adherence not biology and #PrEPaccess depends on politics:

https://t.co/xm2eQW327J

Raphael Landovitz from UCLA’s talk at #AIDS2026 explains why “we may soon be seeing recommendations to harmonise 2:1:1 dosing across populations.”

#PrEPforWomen #HIV

[HIV i-Base @HIViBase]

#PrEP efficacy depends on adherence not biology and #PrEPaccess depends on politics:

https://t.co/xm2eQW327J

Raphael Landovitz from UCLA’s talk at #AIDS2026 explains why “we may soon be seeing recommendations to harmonise 2:1:1 dosing across populations.”

#PrEPforWomen #HIV

[Positively Aware @PosAware]

@NIH tells ACTG, @HIVptn, @HelpEndHIV, @IMPAACTNetwork they should “pause” new clinical trials amidst funding delays. Advocates have issued an open letter to Congress which the public can sign by Oct. 15.
https://t.co/GJbHIAErty

[Academic Medical Education @Academic_MedEdu]

It's 1 week until we meet again in Philadelphia! 💙

Join us for the 17th International Workshop on Aging & HIV, the only global platform for cross-disciplinary exchange on aging with #HIV.

🗓️ 15-16 Oct

📌 Philadelphia, US (hybrid)

Register: https://t.co/UlUYqXAIxM

#HIVAging

[HIV i-Base @HIViBase]

US #HIVresearch priorities shift from basic and clinical to MAGA-defined implementation science in new @NIH report:

https://t.co/79qKvGKLm1

What does this mean for #KeyPopulations & #HIVfunding for new drugs and vaccine trials?

#NIH #NIHfunding #StandUpForScience #EndAIDS2030

[HIV i-Base @HIViBase]

US #HIVresearch priorities shift from basic and clinical to MAGA-defined implementation science in new @NIH report:

https://t.co/79qKvGKLm1

What does this mean for #KeyPopulations & #HIVfunding for new drugs and vaccine trials?

#NIH #NIHfunding #StandUpForScience #EndAIDS2030

[HIV i-Base @HIViBase]

Stopping ART as part of #HIVcure-related research – experiences from the RIO study:

https://t.co/ggpS0ASNFE

Some participants have been able to safely remain off ART for several years. Have the long-term effects on quality of life been accounted for?

#HIV #ATI #HIVtreatment

[HIV i-Base @HIViBase]

Stopping ART as part of #HIVcure-related research – experiences from the RIO study:

https://t.co/ggpS0ASNFE

Some participants have been able to safely remain off ART for several years. Have the long-term effects on quality of life been accounted for?

#HIV #ATI #HIVtreatment

[HIV i-Base @HIViBase]

US ends #HIV support to #Zimbabwe today: “This is not a future risk – it is a present crisis”:

https://t.co/3LUlhOwd14

With an annual shortfall of ~$80-100 million, more than 100,000 preventable deaths and 50,000 new HIV infections are predicted over the next five years.

[HIV i-Base @HIViBase]

US ends #HIV support to #Zimbabwe today: “This is not a future risk – it is a present crisis”:

https://t.co/3LUlhOwd14

With an annual shortfall of ~$80-100 million, more than 100,000 preventable deaths and 50,000 new HIV infections are predicted over the next five years.

[HIV i-Base @HIViBase]

@AIDS_conference @iasociety @BGrinsztejn Hi, do you have an open-access link for the closing session and the rapporteur sessions? :)

[HIV i-Base @HIViBase]

Activists challenge US Government over “shameful” #PEPFAR cuts:

https://t.co/Q1rKsjWGgp

@asia_ilse & others from @HealthGAP, @TAC & @housingworks disrupt this year's @AIDS_conference to demand an end to the ‘America First Global Health Strategy’.

#AIDS2026 #RethinkRebuildRise

[HIV i-Base @HIViBase]

Activists challenge US Government over “shameful” #PEPFAR cuts:

https://t.co/Q1rKsjWGgp

@asia_ilse & others from @HealthGAP, @TAC & @housingworks disrupt this year's @AIDS_conference to demand an end to the ‘America First Global Health Strategy’.

#AIDS2026 #RethinkRebuildRise

[HIV i-Base @HIViBase]

High efficacy continues in open-label extensions to #lenacapavir phase 3 #PrEP studies:

https://t.co/HWn1XtDfBq

Adherence and uptake of the 6-monthly injections was high. One new #HIV transmission in PURPOSE 2 raises questions, but with few details until Thursday.

#AIDS20206